Literature DB >> 2223421

Conjugation pathways in liver disease.

G M Pacifici1, A Viani, M Franchi, S Santerini, A Temellini, L Giuliani, M Carrai.   

Abstract

1. The activities of microsomal glucuronyltransferase and thiomethyltransferase, and those of cytosolic sulphotransferase, acetyltransferase, glutathione transferase and thiomethyltransferase were measured in abnormal (cirrhosis and chronic hepatitis) and normal livers. 2. Glucuronyltransferase and sulphotransferase were investigated with 2-naphthol and ethinyloestradiol as substrates. p-Aminobenzoic acid, benzo(a)pyrene-4,5-epoxide and 2-mercaptoethanol were the substrates of acetyltransferase, glutathione transferase and thiomethyltransferase, respectively. 3. Enzyme activities are expressed as nmol min-1 incubation mg-1 protein and the averages (+/- s.d.) are given. With 2-naphthol as substrate, the glucuronyltransferase activity was 6.55 +/- 4.10 (abnormal liver, n = 33) and 7.81 +/- 4.02 (normal liver, n = 26) (NS); whereas sulphotransferase activity was 0.28 +/- 0.18 (abnormal liver, n = 35) and 0.68 +/- 0.43 (normal liver, n = 26) (P less than 0.01). Glucuronyltransferase activity towards ethinyloestradiol was 102.5 +/- 56.9 (abnormal liver, n = 30) and 107 +/- 59.9 (normal liver, n = 26) (NS), whereas sulphotransferase activity was 57.2 +/- 36.0 (abnormal liver, n = 35) and 122 +/- 67.6 (normal liver, n = 28) (P less than 0.01). Acetyltransferase activity was 0.84 +/- 0.83 (abnormal liver, n = 35) and 3.84 +/- 1.65 (normal liver, n = 26) (P less than 0.01). Glutathione transferase activity was 0.83 +/- 0.68 (abnormal liver, n = 35) and 2.90 +/- 1.59 (normal liver, n = 25) (P less than 0.01) and thiomethyltransferase activity was 1.00 +/- 0.69 (abnormal liver, n = 34) and 3.99 +/- 1.49 (normal liver, n = 25) (P less than 0.01). 4. Liver disease lowers the activities towards the substrates studied of sulphotransferase, acetyltransferase, glutathionetransferase and thiomethyltransferase but not that of glucuronyltransferase.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223421      PMCID: PMC1368146          DOI: 10.1111/j.1365-2125.1990.tb03794.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

Review 1.  Drug metabolism in liver disease.

Authors:  C W Howden; G G Birnie; M J Brodie
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

Review 2.  Clinical pharmacokinetics of oral contraceptive steroids.

Authors:  M L Orme; D J Back; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 3.  The third S.K. & F. Prize lecture, University of London, December 1981. The clinical pharmacology of oral contraceptive steroids.

Authors:  M L Orme
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

4.  Determination of microsomal UDP-glucuronyltransferase in needle-biopsy specimens of human liver.

Authors:  K W Bock; G Brunner; H Hoensch; E Huber; D Josting
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

5.  Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes.

Authors:  G C Farrell; W G Cooksley; L W Powell
Journal:  Clin Pharmacol Ther       Date:  1979-10       Impact factor: 6.875

6.  Sulfotransferase in humans: development and tissue distribution.

Authors:  G M Pacifici; M Franchi; C Colizzi; L Giuliani; A Rane
Journal:  Pharmacology       Date:  1988       Impact factor: 2.547

7.  Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens.

Authors:  A R Boobis; M J Brodie; G C Kahn; D R Fletcher; J H Saunders; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

8.  The effect of alcoholic cirrhosis on the activities of microsomal aldrin epoxidase, 7-ethoxycoumarin O-de-ethylase and epoxide hydrolase, and on the concentrations of reduced glutathione in human liver.

Authors:  K W Woodhouse; F M Williams; E Mutch; P Wright; O F James; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

Review 9.  Hepatic disease and drug pharmacokinetics.

Authors:  R L Williams; R D Mamelok
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

10.  Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro.

Authors:  M J Brodie; A R Boobis; C J Bulpitt; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more
  13 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 2.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 3.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

4.  Influence of cirrhosis on lamotrigine pharmacokinetics.

Authors:  P Marcellin; F de Bony; C Garret; C Altman; V Boige; C Castelnau; P Laurent-Puig; J C Trinchet; P Rolan; C Chen; J P Mamet; R Bidault
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 5.  Drug acetylation in liver disease.

Authors:  M Levy; Y Caraco; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

6.  Interindividual variability in the N-sulphation of desipramine in human liver and platelets.

Authors:  P Romiti; L Giuliani; G M Pacifici
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of newer antibacterial agents in liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

8.  Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments.

Authors:  Fiona V Bϋdingen; Daniel Gonzalez; Amelia N Tucker; Hartmut Derendorf
Journal:  Ther Adv Infect Dis       Date:  2014-02-01

9.  Interaction of Oatp1b2 expression and nonalcoholic steatohepatitis on pravastatin plasma clearance.

Authors:  Erica L Toth; John D Clarke; Iván L Csanaky; Nathan J Cherrington
Journal:  Biochem Pharmacol       Date:  2019-12-25       Impact factor: 5.858

Review 10.  Clinical pharmacokinetics of diacerein.

Authors:  P Nicolas; M Tod; C Padoin; O Petitjean
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.